(HOTH) Hoth Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US44148G1058
HOTH: Skin Treatment, Cancer Therapy, Brain Injury, Alzheimers, Asthma
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, is dedicated to addressing unmet medical needs through innovative therapies. Their pipeline includes HT-001, a topical treatment in Phase II trials for skin disorders linked to tyrosine kinase inhibitor therapy; HT-KIT, targeting mast-cell derived cancers and anaphylaxis; HT-TBI for traumatic brain injury and ischemic stroke; HT-ALZ for Alzheimers and neuroinflammatory diseases; HT-004, an inhalational therapy for asthma and allergies; and HT-003, which treats acne, psoriasis, and inflammatory bowel diseases. Additionally, their BioLexa Platform is in Phase I for eczema, and HT-005 is under development for lupus.
Hoth has established strategic partnerships with institutions like George Washington University and Weill Cornell Medicine, enhancing their research capabilities. Their collaborations underscore a commitment to advancing therapeutic solutions through academic and industry alliances, potentially accelerating drug development.
Additional Sources for HOTH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HOTH Stock Overview
Market Cap in USD | 14m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2019-02-15 |
HOTH Stock Ratings
Growth 5y | -84.5% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -6.76 |
Analysts | 5/5 |
Fair Price Momentum | 0.56 USD |
Fair Price DCF | - |
HOTH Dividends
No Dividends PaidHOTH Growth Ratios
Growth Correlation 3m | 26.8% |
Growth Correlation 12m | -23.3% |
Growth Correlation 5y | -98.3% |
CAGR 5y | -58.19% |
CAGR/Max DD 5y | -0.59 |
Sharpe Ratio 12m | -0.99 |
Alpha | 4.48 |
Beta | -2.25 |
Volatility | 91.85% |
Current Volume | 263.7k |
Average Volume 20d | 324.4k |
As of March 15, 2025, the stock is trading at USD 1.11 with a total of 263,740 shares traded.
Over the past week, the price has changed by +1.83%, over one month by -1.77%, over three months by +37.04% and over the past year by -5.93%.
No, based on ValueRay Analyses, Hoth Therapeutics (NASDAQ:HOTH) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -84.47 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HOTH as of March 2025 is 0.56. This means that HOTH is currently overvalued and has a potential downside of -49.55%.
Hoth Therapeutics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy HOTH.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, HOTH Hoth Therapeutics will be worth about 0.6 in March 2026. The stock is currently trading at 1.11. This means that the stock has a potential downside of -45.95%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 4.5 | 305.4% |
Analysts Target Price | 4.5 | 305.4% |
ValueRay Target Price | 0.6 | -45.9% |